Gilead Sciences: Ireland - Much More than just a Portal to the EU Market




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Gilead Sciences: Ireland - Much More than just a Portal to the EU Market
Released on: July 01, 2008. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this latest edition of The Regional Report, Fintan Walton speaks with Julie O’Neill, General Manager of Gilead Sciences Ireland, to find out what this multi-national pharmaceutical company, based in the U.
  • Summary
  • Company
In this latest edition of The Regional Report, Fintan Walton speaks with Julie O’Neill, General Manager of Gilead Sciences Ireland, to find out what this multi-national pharmaceutical company, based in the U.S., has planned for their future in Ireland. Gilead first came to Ireland through its acquisition of NeXstar in 1999 and, since that time, has increased its staff tenfold and acquired other companies and additional facilities within the country. Originally, Gilead saw Ireland as a portal to the EU market but over time, their positive experience in the country has led to greater investment there. Ms. O’Neill praises the flexibility of the highly educated workforce, the strong compliance focus of Ireland, the ease of doing business in the country, and the tremendous support provided at all levels of government. Gilead is a dynamic company that Julie believes fits well with the dynamic Irish people and they have plans to continue to expand their operations in Ireland, with their new site playing an important role in future clinical trials and new product introductions.
Gilead Sciences